Impact of therapeutic management and geriatric evaluation on patient of eighty years and older with diffuse large B‐cell lymphoma on survival: A systematic review

Abstract

Diffuse large B cell lymphoma (DLBCL) represents 30%-40% of adult non-Hodgkin lymphoma (NHL). 1 DLBCL is a highly aggressive disease, with a limited life expectancy without treatment and a poor prognosis in case of relapse or refractory disease. 2 Its incidence increases with age, with a median age of 70 years at diagnosis. 1 Considering population aging, an increased incidence is expected within the next few years. 3 R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Oncovin, Prednisone) regimen is widely used as a first-line treatment for this